PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Imara offloads sickle cell drug to Cardurion

Imara will be selling its sickle cell disease candidate and all other assets related to its PDE9 program to startup Cardurion Pharmaceuticals, as the struggling Boston biotech deals with a major trial failure.

Imara will divest tovinontrine (IMR-687), a highly selective and potent small molecule inhibitor of phosphodiesterase-9 (PDE9) that the company was studying in both sickle cell disease and beta-thalassemia.

Back in April, Imara posted interim analyses of its Ardent phase 2b trial of tovinontrine in sickle cell disease and the Forte phase 2b trial in beta-thalassemia, concluding that no meaningful benefit was observed in the tovinontrine group compared to the placebo. Both studies, as well as the development of tovinontrine, were discontinued. The company has to reduce its workforce in response to trial failures.

Now, Cardurion, a cardiovascular biotech startup backed by Takeda, will pick up the assets for an upfront payment of $34.75 million and $60 million in milestone payments — in addition to the $250,000 previously paid by Cardurion.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026